文献速递脑血管病外科神经重症

溶栓治疗作为更优选择:慢性硬膜下血肿术后急性硬膜下血肿三例 insights

Thrombolytic Therapy as a Superior Option: Insights from Three Cases of Acute Subdural Hematoma Following Surgery for Chronic Subdural Hematoma.
PubMed 文献 · World Neurosurg · 2024-08-03

本文回顾性分析了51个月内单中心收治的3例老年慢性硬膜下血肿患者,均在急诊顶骨钻孔引流术后发生急性硬膜下血肿;2例接受5万单位尿激酶溶栓,1例接受大骨瓣开颅,均获得满意预后且无显著神经功能缺损。作者提出溶栓治疗可能是慢性硬膜下血肿术后急性硬膜下血肿的潜在更优选择,但证据匮乏,需广泛研究验证其安全性和有效性。

要点

  • 3例老年慢性硬膜下血肿患者术后均发生急性硬膜下血肿。
  • 2例接受5万单位尿激酶溶栓,1例接受大骨瓣开颅。
  • 尿激酶介导的硬膜下溶栓可提高血肿清除率。

核心结论

  • 尿激酶介导的硬膜下溶栓可提高血肿清除率,提示可转向微创治疗以减少更大创伤。
  • 但证据匮乏,需广泛研究验证其安全性和有效性。

研究设计与样本

  • 回顾性评估单中心51个月(2022年2月至2024年5月)内收治的慢性硬膜下血肿患者,报告3例术后急性硬膜下血肿的老年患者,分析潜在致病因素并提出相关策略。

主要发现

  • 3例老年患者均因症状加重急诊入院,术前评估后行急诊顶骨钻孔引流术,术后均发生急性硬膜下血肿。
  • 2例接受5万单位尿激酶溶栓,1例接受大骨瓣开颅。
  • 所有患者均获得满意预后,无显著神经功能缺损。

关键数值与推荐

  • 2例接受5万单位尿激酶溶栓。
  • 1例接受大骨瓣开颅。

临床怎么用

  • 作者提出溶栓治疗可能是慢性硬膜下血肿术后急性硬膜下血肿的潜在更优选择。
  • 作者认为尿激酶介导的硬膜下溶栓可提高血肿清除率,提示可转向微创治疗以减少更大创伤。
  • 作者指出证据匮乏,需广泛研究验证其安全性和有效性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chronic subdural hematoma (cSDH) ranks among the most prevalent neurosurgical conditions, with burr-hole drainage typically yielding favorable prognoses. Nevertheless, perioperative complications may arise, with remote intraparenchymal hemorrhage and subarachnoid hemorrhage occurring infrequently, while acute subdural hematoma (aSDH) remains a relatively common complication post-cSDH removal. The standard treatment for aSDH, typically large craniotomy, substantially elevates surgical risk. METHODS AND RESULTS: Patients admitted over the course of 51 months (February 2022 to May 2024) to a single institution for treatment of cSDH were retrospectively evaluated, with three cases of postoperative aSDH in elderly patients with cSDH, examining potential causative factors and proposing pertinent strategies. Three elderly patients, admitted urgently due to exacerbating symptoms, underwent preoperative assessment followed by emergency parietal burr-hole drainage. Regrettably, all three patients developed aSDH postoperatively. Various treatment approaches were employed: two cases received thrombolysis with 50,000 units of urokinase, while one case required a large craniotomy. Despite the patients achieving satisfactory outcomes without significant neurological deficits, this study advocates thrombolytic therapy as a potentially superior option for aSDH following cSDH surgery. CONCLUSION: Urokinase-mediated subdural thrombolysis enhances hematoma clearance rates, suggesting a shift toward minimally invasive treatments to mitigate greater trauma. However, the paucity of evidence necessitates extensive research to validate its safety and efficacy.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Du X, Wang C, Qian J, et al. Thrombolytic Therapy as a Superior Option: Insights from Three Cases of Acute Subdural Hematoma Following Surgery for Chronic Subdural Hematoma. World Neurosurg. 2024. PMID: 39098501. doi:10.1016/j.wneu.2024.07.195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。